<DOC>
	<DOCNO>NCT02464826</DOCNO>
	<brief_summary>This study design demonstrate efficacy product non-dermatophyte ( Scytalidium dimidiatum ) onychomycosis chronic paronychia treatment Thai patient .</brief_summary>
	<brief_title>A Pilot Study - Safety Efficacy Nailprotex® Onychomycosis Treatment</brief_title>
	<detailed_description>Onychomycosis common superficial fungal skin infection general population . According previous study , prevalence tinea pedis onychomycosis general Thai population 3.8 % 1.7 % respectively . However , problem neglect treatment due asymptomatic clinical manifestation low effect quality life . In Thailand , previous study report aetiological pathogen disorder non-dermatophyte mold ( 51.6 % ) , dermatophyte ( 36.3 % ) yeast ( 6 % ) . Additionally , Scytalidium dimidiatum majority causative agent non-dermatophyte mold . Systemic therapy azoles group terbinafine recommend standard management tinea capitis . In contrast , prolonged course may induce serious side effect . So topical therapy alternative treatment old patient limited drug usage . Especially , non-dermatophyte onychomycosis recalcitrant condition . Moreover , none standard regimen recommend . Nailprotex® novel topical treatment onychomycosis chronic paronychia . The active ingredient phenol extract Olea European leaf . It able inhibit fungal growth . Additionally , product apply nail care many European country 10 year . The serious side effect never report . Therefore , study design demonstrate efficacy product non-dermatophyte ( Scytalidium dimidiatum ) onychomycosis chronic paronychia treatment Thai patient .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Paronychia</mesh_term>
	<criteria>Male female participant 18 year old . Participants diagnose Scytalidium dimidiatum onychomycosis chronic paronychia dermatologist base clinical presentation mycological identification . Participants accept aim project sign consent form . Participants nail disorder participate research . Participants history immunocompromised host . Participants diagnose onychomycosis 3 nail matrix involvement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Onychomycosis</keyword>
	<keyword>Chronic paronychia</keyword>
	<keyword>Treatment</keyword>
</DOC>